Matthew C H J Morrall1,2, Rosa Reed-Berendt3, Kate Moss3, Helen Stocks3, Alexandra L Houston3, Poppy Siddell3, Susan Picton4, Richard Grundy5. 1. Paediatric Neuropsychology, The Leeds Teaching Hospitals NHS Trust, E Floor, Martin Wing, Leeds General Infirmary, Leeds, LS1 3EX, UK. m.morrall@nhs.net. 2. Consultant Paediatric Neuropsychologist, Paediatric Neuropsychology, E Floor, Martin Wing, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK. m.morrall@nhs.net. 3. Paediatric Neuropsychology, The Leeds Teaching Hospitals NHS Trust, E Floor, Martin Wing, Leeds General Infirmary, Leeds, LS1 3EX, UK. 4. Paediatric Oncology, The Leeds Teaching Hospitals NHS Trust, D Floor, Martin Wing, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK. 5. Children's Brain Tumour Research Centre, Academic Division of Child Health, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2RD, UK.
Abstract
PURPOSE: This is the first UK multi-centre case-controlled study with follow-up in excess of 10 years to report the neurocognitive, academic and psychological outcomes of individuals diagnosed with a brain tumour in early childhood. Children enrolled into the UKCCSG CNS 9204 trial, diagnosed with intracranial ependymoma when aged ≤ 36 months old, who received a primary chemotherapy strategy to defer or avoid radiotherapy, were recruited. METHODS: Outcomes of those who relapsed and subsequently received radiotherapy (n = 13) were compared to those enrolled who did not relapse (n = 16), age-matched controls-diagnosed with solid non-central nervous system (SN-CNS; n = 15) tumours or low-grade posterior fossa pilocytic astrocytoma (PFPA; n = 15), and normative data. Analyses compared nine neurocognitive outcomes as primary measures with quality of survival as secondary measures. RESULTS: Relapsed ependymoma participants performed significantly worse than their non-relapsed counterparts on measures of Full Scale IQ, Perceptual Reasoning, Word Reading and Numerical Operations. The relapsed ependymoma group performed significantly worse than SN-CNS controls on all primary measures, whereas non-relapsing participants only differed significantly from SN-CNS controls on measures of Processing Speed and General Memory. Relapsed ependymoma participants fared worse than all groups on measures of quality of survival. CONCLUSIONS: The relapsed irradiated ependymoma group demonstrated the most significantly impaired neurocognitive outcomes at long-term follow-up. Non-relapsing participants demonstrated better outcomes than those who relapsed. Results tentatively suggest avoiding radiotherapy helped preserve neurocognitive and learning outcomes of individuals diagnosed with ependymoma when aged ≤ 36 months old. Prospective neurocognitive surveillance is required. Recommendations for clinical and research practice are provided.
PURPOSE: This is the first UK multi-centre case-controlled study with follow-up in excess of 10 years to report the neurocognitive, academic and psychological outcomes of individuals diagnosed with a brain tumour in early childhood. Children enrolled into the UKCCSG CNS 9204 trial, diagnosed with intracranial ependymoma when aged ≤ 36 months old, who received a primary chemotherapy strategy to defer or avoid radiotherapy, were recruited. METHODS: Outcomes of those who relapsed and subsequently received radiotherapy (n = 13) were compared to those enrolled who did not relapse (n = 16), age-matched controls-diagnosed with solid non-central nervous system (SN-CNS; n = 15) tumours or low-grade posterior fossa pilocytic astrocytoma (PFPA; n = 15), and normative data. Analyses compared nine neurocognitive outcomes as primary measures with quality of survival as secondary measures. RESULTS: Relapsed ependymomaparticipants performed significantly worse than their non-relapsed counterparts on measures of Full Scale IQ, Perceptual Reasoning, Word Reading and Numerical Operations. The relapsed ependymoma group performed significantly worse than SN-CNS controls on all primary measures, whereas non-relapsing participants only differed significantly from SN-CNS controls on measures of Processing Speed and General Memory. Relapsed ependymomaparticipants fared worse than all groups on measures of quality of survival. CONCLUSIONS: The relapsed irradiated ependymoma group demonstrated the most significantly impaired neurocognitive outcomes at long-term follow-up. Non-relapsing participants demonstrated better outcomes than those who relapsed. Results tentatively suggest avoiding radiotherapy helped preserve neurocognitive and learning outcomes of individuals diagnosed with ependymoma when aged ≤ 36 months old. Prospective neurocognitive surveillance is required. Recommendations for clinical and research practice are provided.
Entities:
Keywords:
Brain tumour; Ependymoma; Neurocognitive; Outcome; Paediatric; Quality of survival
Authors: J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: Shawna L Palmer; John O Glass; Yimei Li; Robert Ogg; Ibrahim Qaddoumi; Gregory T Armstrong; Karen Wright; Cynthia Wetmore; Alberto Broniscer; Amar Gajjar; Wilburn E Reddick Journal: Neuro Oncol Date: 2012-08-16 Impact factor: 12.300
Authors: Catherine Godfraind; Joanna M Kaczmarska; Mehmet Kocak; James Dalton; Karen D Wright; Robert A Sanford; Fredrick A Boop; Amar Gajjar; Thomas E Merchant; David W Ellison Journal: Acta Neuropathol Date: 2012-04-21 Impact factor: 17.088
Authors: Jennifer A Limond; Kim S Bull; Gabriele Calaminus; Colin R Kennedy; Helen A Spoudeas; Mathilde P Chevignard Journal: Eur J Paediatr Neurol Date: 2014-12-17 Impact factor: 3.140
Authors: Ellen van der Plas; Brian J Nieman; Darci T Butcher; Johann K Hitzler; Rosanna Weksberg; Shinya Ito; Russell Schachar Journal: J Can Acad Child Adolesc Psychiatry Date: 2015-03-04
Authors: Amr H Saleh; Nardin Samuel; Kyle Juraschka; Mohammad H Saleh; Michael D Taylor; Michael G Fehlings Journal: Nat Rev Cancer Date: 2022-01-14 Impact factor: 69.800
Authors: Yuliang Wang; Anthony Pak Yin Liu; Tatia Mei-Chun Lee; Wilfred Hing Sang Wong; Daniel Yee Tak Fong; Lok Kan Leung; Matthew Ming Kong Shing; Dennis Tak-Loi Ku; Godfrey Chi-Fung Chan; Winnie Wan-Yee Tso Journal: Cancers (Basel) Date: 2022-07-04 Impact factor: 6.575
Authors: Pierre Leblond; Maura Massimino; Martin English; Timothy A Ritzmann; Lorenza Gandola; Gabriele Calaminus; Sophie Thomas; David Pérol; Julien Gautier; Richard G Grundy; Didier Frappaz Journal: Front Neurol Date: 2022-06-02 Impact factor: 4.086
Authors: Niki Jurbergs; Jennifer L Harman; Ansley E Kenney; Katherine Semenkovich; Andrew E Molnar; Victoria W Willard Journal: Children (Basel) Date: 2019-11-19